EUVIMEDEUVIMED entdecken
Open Access · CC0

Rapid detection of non-rifampicin resistant drug-resistant tuberculosis using Xpert MTB/XDR testing: Findings from a multisite drug-resistant tuberculosis case detection surge in Zambia

Phallon Blessing Mwaba iD, Marshal Sikandangwa iD, Robertson Chibumbya, Innocent Mwaba iD, Minyoi Mubita Maimbolwa, Chitalu Chanda iD, Muhammad Mputu, Rhehab Chimzizi, Kevin Mabvuto Zimba, Nancy Kasese Chanda iD, Angel Mubanga, Monde Muyoyeta iD und 1 weitere

PLOS Global Public Health · 23.09.2026 · 6 (9) · e0005536

DOI: 10.1371/journal.pgph.0005536 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Global Public Health, online erschienen am 23.09.2026. Verfasst von Phallon Blessing Mwaba und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tuberculosis and other Respiratory Diseases, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: USAID Zambia.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zambia continues to face a high-Tuberculosis burden with rising drug resistance, yet diagnosis of non-rifampicin resistant drug-resistance remains limited due to reliance on rifampicin as a proxy for multidrug-resistant tuberculosis. The Xpert MTB/XDR assay offers a rapid detection of resistance to isoniazid, fluoroquinolone, Ethionamide and aminoglycosides, addressing a major diagnostic gap. The aim of this analysis was to describe the prevalence and profile of drug resistance among bacteriologically confirmed TB patients subjected to reflex Xpert MTB/XDR testing. We conducted an analysis of programmatic data from a four-week active drug-resistant TB case finding surge in May 2025, implemented across 39 high-TB burden facilities in five provinces of Zambia. We re-evaluated eligible Xpert MTB/RIF Ultra positive TB patients using the Xpert MTB/XDR platform regardless of Rifampicin resistance to identify additional drug resistance beside rifampicin. We analyzed patient demographics, characteristics, and the distribution of drug resistance drug-resistance categories descriptively. Of 509 TB patients identified, 70.9%(n = 360) were bacteriologically confirmed by Xpert MTB/RIF Ultra among whom 92.8%(n = 336) were eligible for reflex Xpert MTB/XDR testing. Of the eligible, 89.3% (n = 313) underwent reflex Xpert MTB/XDR testing. Results were successfully retrieved for 282 (90.1%). Overall, 8.5%(n = 24) of patients with XDR results had a form of drug-resistant tuberculosis. Mono-resistance to rifampicin (3.5%, n = 10) or isoniazid (3.2%, n = 9) was more prevalent than multi-drug-resistant tuberculosis (1.1%, n = 3), while only 0.4% (n = 1) had Pre-XDR TB. Non-rifampicin resistant drug-resistance, including isoniazid mono-resistance and isoniazid combined with fluoroquinolone or ethionamide resistance, were detected in 3.2% (n = 9) of all patients with XDR TB results (37.5% of all DR-TB cases). Reflex Xpert MTB/XDR testing enabled rapid identification of non-rifampicin-resistance drug-resistant TB cases that would have been missed by rifampicin-centric diagnostics. Strengthening the integration of MTB/XDR into routine diagnostic algorithms can improve early drug-resistant tuberculosis detection, guide individualized treatment, and prevent amplification of resistance in high-burden settings.

Autor:innen und Institutionen

  • Department of Tuberculosis and other Respiratory Diseases, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
  • Department of Public Health, Ministry of Health, Zambia, National Tuberculosis and Leprosy Programme, Lusaka, Zambia.
  • Health Coordination Office, United States Embassy, Lusaka, Zambia.

ORCID-Profile: Phallon Blessing Mwaba, Marshal Sikandangwa, Innocent Mwaba, Chitalu Chanda, Nancy Kasese Chanda, Monde Muyoyeta

Förderung

  • USAID Zambia

Zitieren

APA

Mwaba, P. B., Sikandangwa, M., Chibumbya, R., Mwaba, I., Maimbolwa, M. M., Chanda, C., Mputu, M., Chimzizi, R., Zimba, K. M., Chanda, N. K., Mubanga, A., Muyoyeta, M., & Kagujje, M. (2026). Rapid detection of non-rifampicin resistant drug-resistant tuberculosis using Xpert MTB/XDR testing: Findings from a multisite drug-resistant tuberculosis case detection surge in Zambia. PLOS Global Public Health, 6(9), e0005536. https://doi.org/10.1371/journal.pgph.0005536

Vancouver

Mwaba PB, Sikandangwa M, Chibumbya R, Mwaba I, Maimbolwa MM, Chanda C, et al. Rapid detection of non-rifampicin resistant drug-resistant tuberculosis using Xpert MTB/XDR testing: Findings from a multisite drug-resistant tuberculosis case detection surge in Zambia. PLOS Global Public Health. 2026;6(9):e0005536. doi:10.1371/journal.pgph.0005536

BibTeX
@article{Mwaba2026,
  author = {Mwaba, Phallon Blessing and Sikandangwa, Marshal and Chibumbya, Robertson and Mwaba, Innocent and Maimbolwa, Minyoi Mubita and Chanda, Chitalu and Mputu, Muhammad and Chimzizi, Rhehab and Zimba, Kevin Mabvuto and Chanda, Nancy Kasese and Mubanga, Angel and Muyoyeta, Monde and Kagujje, Mary},
  title = {Rapid detection of non-rifampicin resistant drug-resistant tuberculosis using Xpert MTB/XDR testing: Findings from a multisite drug-resistant tuberculosis case detection surge in Zambia},
  journal = {PLOS Global Public Health},
  year = {2026},
  volume = {6},
  number = {9},
  pages = {e0005536},
  doi = {10.1371/journal.pgph.0005536}
}
Kostenlos starten →